ADAP 2Q24 Earnings: Tecelra FDA Approval + Capital Reload
Key 2Q24 takeaways include: 1) recent FDA approval of Tecelra (afami-cel) triggers immediate onboarding of Authorized Treatment Centers (ATCs),...
144 Views
ADAP: Initiating Coverage of Leading T-Cell Therapy Company
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a biopharmaceutical company focused on designing, developing, and delivering innovative cell...
178 Views
Biopharma Week in Review
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
10 Views
No more insights